ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Antipsychotic Response in Schizophrenia

This study has been completed.

Sponsored by: Department of Veterans Affairs
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00018668
  Purpose

Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental illness. Prior research has lead to a novel instrumental approach for distinguishing subtypes of motor slowing - one type related to cognitive processes and another related to parkinsonism. The purpose of this study is to test whether new medications used to treat schizophrenia improve the cognitive or parkinsonian components of motor slowing. Patients will be studied in the laboratory before and 8-weeks after starting a new antipsychotic. The n of this study = 60 patients. The results of this study will improve our understanding of the complex interactions between cognitive processing and motor behavior in patients with psychotic illnesses and how drugs work to treat these problems.


Condition Intervention Phase
Schizophrenia
Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine
Phase IV

MedlinePlus related topics:   Schizophrenia   

ChemIDplus related topics:   Risperidone    Quetiapine    Quetiapine fumarate    Olanzapine   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:   Psychopharmacologic Aspects of Motor Slowing in Schizophrenia

Further study details as provided by Department of Veterans Affairs:

Study Start Date:   October 2000
Estimated Study Completion Date:   September 2004

  Eligibility
Ages Eligible for Study:   21 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Schizophrenia diagnosis currently treated with conventional antipsychotic willing to be switched to an atypical antipsychotic.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018668

Locations
United States, California
Department of Veterans Affairs    
      San Diego, California, United States, 92161

Sponsors and Collaborators
  More Information


Study ID Numbers:   MHBS-041-00S
First Received:   July 3, 2001
Last Updated:   November 3, 2005
ClinicalTrials.gov Identifier:   NCT00018668
Health Authority:   United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Antipsychotics  
schizophrenia  
motor retardation  
bradykinesia  

Study placed in the following topic categories:
Schizophrenia
Quetiapine
Dopamine
Mental Disorders
Risperidone
Olanzapine
Psychotic Disorders
Serotonin
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Gastrointestinal Agents
Psychotropic Drugs
Antiemetics
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Antagonists
Serotonin Agents
Autonomic Agents
Therapeutic Uses
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers